Amphastar Pharmaceuticals (AMPH) Finished Goods (2015 - 2026)

Amphastar Pharmaceuticals' Finished Goods history runs 12 years deep, the most recent figure standing at $22.9 million for Q1 2026.

• On a quarterly basis, Finished Goods fell 40.46% year-over-year to $22.9 million in Q1 2026; TTM through Mar 2026 was $22.9 million, a 40.46% decrease from a year earlier, with the FY2025 full-year figure at $29.6 million, down 24.87% from the prior year.
• Finished Goods retreated to $22.9 million in Q1 2026 per AMPH's latest filing, from $29.6 million in the prior quarter.
• Across five years, Finished Goods topped out at $41.6 million in Q2 2025 and bottomed at $14.5 million in Q1 2022.
• The 5-year median for Finished Goods is $27.4 million (2024), against an average of $27.8 million.
• Across the five-year window, Finished Goods soared 91.35% in 2023 and tumbled 40.46% in 2026, its largest moves.
• Year by year, Finished Goods stood at $18.9 million in 2022, then jumped by 31.99% to $24.9 million in 2023, then surged by 58.14% to $39.4 million in 2024, then slipped by 24.87% to $29.6 million in 2025, then decreased by 22.71% to $22.9 million in 2026.
• Per Business Quant, the three latest AMPH Finished Goods figures stand at $22.9 million (Q1 2026), $29.6 million (Q4 2025), and $37.7 million (Q3 2025).